Heal House Vitiligo Research 78 · Original Article
Can a blood test tell if your vitiligo is spreading now?
Clinical Importance of Autoantibodies to SOX10 and Lamin A/C as Potential Biomarkers in Sera From Vitiligo Patients
Final review
In short
We confirmed that SOX10 antibodies in the blood can be a marker indicating whether vitiligo is currently spreading. These antibodies were found more often in active spreading vitiligo.
A persistent challenge in vitiligo is determining whether the disease is currently stable or spreading. Until now, we have largely relied on visible changes. No blood test was available to provide this information. Therefore, multiple hospitals joined forces to examine whether two antibodies (SOX10 and lamin A/C) in the blood of vitiligo patients could serve as a mirror reflecting disease activity. I participated in this study as a co-investigator.
Q1 What did this study measure and how?
We measured the levels of two antibodies, SOX10 and lamin A/C, in the blood of 80 adult vitiligo patients. We then compared these levels with whether the disease was spreading and its type. The median age of the 80 participants was 60 years. Among them, 56 (70%) had nonsegmental vitiligo, and 27 (approximately 34%) had active (spreading) disease. Antibodies were measured using a precise blood test method. Because this was a multicenter prospective study that collected data collaboratively, the results are more reliable. The table below summarizes the study framework.
Study at a Glance
| Item | Content |
|---|---|
| Target | 80 adult vitiligo patients (multicenter prospective) |
| Component | Nonsegmental 56 (70%), active 27 (approximately 34%) |
| Measurement | SOX10 and lamin A/C autoantibodies in blood (ELISA) |
| Detection rate | SOX10 35.0%, lamin A/C 71.3% |
Q2 What was the most important finding?
The key finding is that the SOX10 antibody was much more frequently detected in vitiligo that is currently spreading. In patients with active disease, 59.3% tested positive for this antibody. In those with stable disease, only 24.5% tested positive. This means it was more than twice as common during active spread. In contrast, the lamin A/C antibody showed no significant difference between the two states. Between the two antibodies, SOX10 appears to be a better marker for reflecting disease activity. The table below shows the difference.
SOX10 antibody detection rate — active vs. stable vitiligo
| Vitiligo status | SOX10 antibody detection rate | In simple terms |
|---|---|---|
| Active (spreading) | 59.3% | Detected in more than half |
| Stable (not spreading) | 24.5% | Detected in about one in four |
Q3 Why does this test matter?
Until now, determining whether vitiligo is spreading has largely depended on visible changes. A blood-based marker could provide a clearer assessment. SOX10 is a protein found inside pigment cells. Therefore, when the immune system actively destroys pigment cells, antibodies to these fragments are thought to increase. In other words, a high level of this antibody may signal that pigment cells are currently under attack. However, it is not detected in all patients. Even among those with active disease, it was found in only about six out of ten. Further confirmation in larger patient groups is still needed. Nevertheless, the significance lies in finding a clue to read the disease state from a single drop of blood.
Closing remarks
One of the most frustrating moments in vitiligo is when it is difficult to say for sure whether the disease is currently spreading. This study adds a new hint—a blood test—to that question. It is not yet a test that can be used directly in the clinic. Still, I believe it is a seed that may help us more clearly identify periods of spread and determine the timing of treatment in the future.
